Lai Quirino, Di Pietro Verdiana, Iesari Samuele, Amabili Sofia, De Luca Linda, Clemente Katia, Famulari Antonio, Pisani Francesco
Transplant Unit, Department of Surgery, University of L'Aquila, San Salvatore Hospital, L'Aquila, Italy.
Blood Purif. 2015;40(3):218-22. doi: 10.1159/000437042. Epub 2015 Sep 2.
Coupled plasma filtration adsorption (CPFA) is an extracorporeal treatment based on plasma filtration associated with an adsorbent cartridge and hemofiltration. CPFA is able to remove inflammatory mediators and it has been used to treat severe sepsis, septic shock and multiple organ dysfunction syndrome. Limited experience exists on the use of CPFA after solid organ transplantation. We report our experience with CPFA in 2 kidney transplant recipients with post-nephrolithotomy septic shock and severe unexplained rhabdomyolysis. In both the cases, excellent results were observed. In selected cases, CPFA can be safely and effectively used in patients with a solid organ transplant. However, additional studies are needed in this particular setting, to further investigate the potential role of CPFA for the treatment of other conditions associated with excessive inflammation, such as in rheumatologic disorders and delayed graft function.
配对血浆滤过吸附（CPFA）是一种基于血浆滤过并与吸附柱和血液滤过相结合的体外治疗方法。CPFA能够清除炎症介质，已被用于治疗严重脓毒症、脓毒性休克和多器官功能障碍综合征。实体器官移植后使用CPFA的经验有限。我们报告了2例肾移植受者在肾切开取石术后发生脓毒性休克和严重不明原因横纹肌溶解症时使用CPFA的经验。在这两个病例中，均观察到了良好的效果。在特定病例中，CPFA可安全有效地用于实体器官移植患者。然而，在这种特殊情况下还需要进一步研究，以进一步探讨CPFA在治疗其他与过度炎症相关疾病（如风湿性疾病和移植肾功能延迟）中的潜在作用。
